Investors

Press Releases

Date Title View
Toggle Summary Momenta Pharmaceuticals Announces Publication of Phase 1 Study Data for Anti-FcRn Antibody, M281
Full data shows safety, tolerability and proof-of-mechanism in healthy volunteers CAMBRIDGE, Mass. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced the publication of results from its Phase 1 study of M281 in healthy volunteers in the online edition
View HTML
Toggle Summary Momenta Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today reported its financial results for the third quarter ended September 30, 2018 and provided a corporate update. “We recently highlighted our pipeline of novel drug candidates for immune-mediated
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Global Settlement with AbbVie to Enable Commercialization of M923, a Proposed Biosimilar to HUMIRA® (adalimumab)
CAMBRIDGE, Mass. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced that it has executed agreements with AbbVie Inc. , providing license rights for the global launch of M923, Momenta’s proposed biosimilar to HUMIRA.
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at the Stifel 2018 Healthcare Conference
CAMBRIDGE, Mass. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), today announced that it will present at the Stifel 2018 Healthcare Conference. The presentation is scheduled for Tuesday, November 13, 2018 at 10:15 A.M.
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Date of Third Quarter 2018 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass. , Oct. 31, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), today announced that it will release its financial results for the third quarter ended September 30, 2018 and provide a corporate update before the U.S.
View HTML
Toggle Summary Momenta Pharmaceuticals to Host R&D Day on October 11, 2018
CAMBRIDGE, Mass. , Oct. 04, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA)  today announced that it will host a live webcast of its R&D Day on Thursday, October 11, 2018 beginning at 8:30 am ET . The event is being held in New York, NY .
View HTML
Toggle Summary Momenta Pharmaceuticals Completes Strategic Review to Refocus its Operations and Drive Shareholder Value
    -- Company to Prioritize Pipeline of Novel Drug Candidates for Immune-Mediated Diseases and Reduce Investment in Biosimilars by Focusing on Two Later-stage Assets -- -- Company to Streamline Operations Through Corporate Restructuring -- CAMBRIDGE, Mass. , Oct.
View HTML
Toggle Summary Momenta Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the second quarter ended June 30, 2018 and provided a corporate update. “The strategic review of our business announced earlier this year is progressing and we
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Date of Second Quarter 2018 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), today announced that it will release its financial results for the second quarter ended June 30, 2018 and provide a corporate update before the U.S. financial markets open on Thursday, August 9 ,
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 39th Annual Global Healthcare Conference
CAMBRIDGE, Mass. , June 06, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), today announced that it will present at the Goldman Sachs 39th Annual Global Healthcare Conference .  The presentation is scheduled for Wednesday, June 13, 2018 at 2:40 P.M. PT / 5:40 P.M. ET .
View HTML